Ald-Ph-PEG4-bis-PEG3-methyltetrazine

Cat. No.: HY-130974: Data Sheet Handling Instructions
FAQs
Technical Support

Ald-Ph-PEG4-bis-PEG3-methyltetrazine is a cleavable 7 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Ald-Ph-PEG4-bis-PEG3-methyltetrazine is a click chemistry reagent, it contains a Tetrazine group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing TCO groups.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Ald-Ph-PEG4-bis-PEG3-methyltetrazine 화학구조

사이즈		재고
MOQ		Minimum order quantity
50 mg		견적 받기
100 mg		견적 받기
250 mg		견적 받기
Other size		견적 받기

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All ADC Linker Isoform Specific Products:

View All Isoforms

Cleavable Linker Non-cleavable Linker Acid Cleavable Linker Disulfide Cleavable Linker Protease Cleavable Linker Glycosidase Cleavable Linker Phosphatase Cleavable Linker

Biological Activity
순도&문서
References
고객리뷰

제품 설명

Ald-Ph-PEG4-bis-PEG3-methyltetrazine is a cleavable 7 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)^[1]. Ald-Ph-PEG4-bis-PEG3-methyltetrazine is a click chemistry reagent, it contains a Tetrazine group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing TCO groups.

IC₅₀ & Target

Cleavable Linker

In Vitro

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

분자량

1387.53

화학식

C₆₆H₉₄N₁₄O₁₉

SMILES

O=C(CCOCCOCCOCCOCCNC(C1=CC=C(C=O)C=C1)=O)NC(COCCC(NCCOCCOCCOCCNC(CC2=CC=C(C3=NN=C(C)N=N3)C=C2)=O)=O)COCCC(NCCOCCOCCOCCNC(CC4=CC=C(C5=NN=C(C)N=N5)C=C4)=O)=O

선적

Room temperature in continental US; may vary elsewhere.

보관

Please store the product under the recommended conditions in the Certificate of Analysis.

순도&문서

Handling Instructions (2659 KB)

References

[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337. [Content Brief]